INCMGA00012 in Combination With Other Therapies in Patients With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2023-01-22
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety, preliminary evidence of clinical
activity, and recommended Phase 2 dose (RP2D) of INCMGA00012 in combination with other agents
that may improve the therapeutic efficacy of anti-PD-1 monotherapy.